Wen X Chen

US Patent:

7115556, Oct 3, 2006

Filed:

May 8, 2002

Appl. No.:

10/140293

Inventors:

Wen Y. Chen - Simpsonville SC, US
Thomas E. Wagner - Greer SC, US

Assignee:

Greenville Hospital System - Greenville SC

International Classification:

A61K 38/00

US Classification:

514 2, 530350

Abstract:

The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.

US Patent:

7201905, Apr 10, 2007

Filed:

Mar 23, 2001

Appl. No.:

09/815306

Inventors:

Wen Y. Chen - Simpsonville SC, US
Thomas E. Wagner - Greer SC, US

Assignee:

Greenville Hospital System - Greenville SC

International Classification:

A61K 39/00

US Classification:

4241921, 4241851, 42419511

Abstract:

A novel fusion protein, comprising a receptor-antagonizing domain and a positive immunomodulator domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-interleukin 2 (hPRLA-IL-2) fusion protein combines apoptosis induction and immuno-therapy to combat cancer in the breast or prostate.

US Patent:

7582726, Sep 1, 2009

Filed:

Nov 10, 2004

Appl. No.:

10/985013

Inventors:

Wen Yuan Chen - Simpsonville SC, US
Jang P. Park - Greenville SC, US

Assignee:

GHC Research Development Corporation - Greenville SC

International Classification:

A61K 38/16
A61K 38/17
C07K 14/47

US Classification:

530324, 530350, 4241851

Abstract:

The present invention describes an approach to cancer therapy utilizing novel VEGF receptor antagonists. Specifically, the invention provides peptides and polynucleotides encoding VEGF receptor antagonists and methods of use thereof.

US Patent:

8648046, Feb 11, 2014

Filed:

Nov 17, 2010

Appl. No.:

12/948329

Inventors:

Wen Y. Chen - Greer SC, US

Assignee:

Oncolix, Inc. - Houston TX

International Classification:

A61K 38/00
C07K 7/06

US Classification:

514 193, 514 115, 514 198, 514 212, 530350, 5303877

Abstract:

The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.

US Patent:

20050271626, Dec 8, 2005

Filed:

Mar 8, 2005

Appl. No.:

11/073927

Inventors:

Wen Chen - Simpsonville SC, US
Michele Scotti - Whitehouse Station NJ, US

International Classification:

A61K048/00
A61K038/22

US Classification:

424093200, 514012000, 514044000

Abstract:

The present invention describes compositions and methods for inhibiting cell proliferation comprising a prolactin receptor antagonist and an agent that inactivates the HER2/neu signaling pathway, and methods of use thereof.

US Patent:

20070060520, Mar 15, 2007

Filed:

Aug 4, 2006

Appl. No.:

11/498962

Inventors:

Wen Chen - Simpsonville SC, US
Thomas Wagner - Greer SC, US

International Classification:

A61K 38/22
A61K 31/138

US Classification:

514012000, 514651000

Abstract:

The present invention relates to variant forms of human prolactin which act as antagonists at the prolactin receptor, and to the use of such variants in the treatment of human cancers and proliferative disorders, including both benign and malignant diseases of the breast and prostate.

US Patent:

20100041598, Feb 18, 2010

Filed:

Oct 19, 2006

Appl. No.:

12/083865

Inventors:

Wen Yuan Chen - Greer SC, US

International Classification:

A61K 38/22
A61P 5/06
A61P 35/00

US Classification:

514 12

Abstract:

The present invention relates to compositions and methods for treating cancer. In particular, the invention describes prolactin containing compositions for the prophylactic treatment of breast cancer.

US Patent:

20100215577, Aug 26, 2010

Filed:

Feb 16, 2010

Appl. No.:

12/706702

Inventors:

WEN Y. CHEN - Greer SC, US

Assignee:

ONCOLIX, INC. - Houston TX

International Classification:

A61K 51/08
A61K 38/22
A61K 49/00
A61P 35/00

US Classification:

424 169, 514 12, 424 91

Abstract:

The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial (uterine) cancer with metastases; and visualizing the cancer cells in patient's body. The compositions of the instant invention include human prolactin receptor antagonist G129R.

Author:

Wen Jeng Chen

ISBN #:

0873394399